MedTrace Logo

Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets

NCT04171453 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-06-21

No results posted yet for this study

Summary

This is an open-label, non-comparative, non-interventional, prospective, and multi-center PMS study to observe safety and effectiveness of Lyrica CR (82.5mg, 165mg, 330mg) in Korean subjects under the actual condition of use. PMS is an obligation to K-MFDS.

Conditions

  • Peripheral Neuropathic Pain

Interventions

DRUG

Lyrica CR (Pregabalin)

Lyrica CR 82.5mg, 165mg, or 330mg OD

Sponsors & Collaborators

  • Viatris Korea

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2022-07-14
Completion
2022-07-14
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04171453 on ClinicalTrials.gov